CEO Michel Vanbrabant will present the company’s latest positive developments and an ambitious 2021 roadmap for iSTAR Medical at the Biocapital Europe meeting on 11 March.
A number of data announcements in 2020 consistently showed positive outcomes for iSTAR Medical’s Minimally Invasive Glaucoma Surgery (MIGS) device MINIject in over 130 patients across trial sites in Europe, the Americas and Asia.
The promising ongoing performance of MINIject in trials so far is setting the scene for an ambitious roadmap for 2021, with commercial launch and expansion to the U.S. on the horizon
, Vanbrabant explained.
BioCapital Europe is Europe’s premier life sciences investment conference, offering VCs and Institutional Investors unique and timely access to around 40 exciting biotech, medtech and diagnostics companies from the Benelux and Europe.
